What diseases does Imatinib (Gleevec) mainly treat and its indications?

Imatinib (Imatinib) is an oral tyrosine kinase inhibitor, a typical representative of targeted therapy drugs, which mainly inhibits BCR-ABLtyrosine kinase, c-KITreceptor tyrosine kinase and PDGFR (platelet-derived growth factor receptor) signaling pathways, thereby blocking the proliferation of malignant cells and promoting apoptosis. This mechanism enables imatinib to have broad clinical application value in a variety of malignant tumors and hematological diseases, especially in patients with chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).

First of all, imatinib is most widely used in chronic myelogenous leukemia (CML). CML is a myeloproliferative disease driven by the BCR-ABL fusion gene, which produces abnormal tyrosine kinase activity, leading to unlimited proliferation of leukemia cells. Imatinib specifically inhibits BCR-ABL kinase and blocks abnormal signaling pathways, thereby significantly improving the clinical prognosis of CML patients. Clinical studies have shown that for patients with CML in the chronic phase, imatinib can achieve a complete hematological response rate of more than 90% and a complete cellular molecular response rate of more than 70%, significantly extending the progression-free survival and overall survival of patients.

Secondly, imatinib also plays an important role in the treatment of gastrointestinal stromal tumors (GIST). GISTis mostly driven by c-KIT or PDGFRα gene mutations, whose abnormal receptor tyrosine kinase activation promotes tumor cell proliferation and survival. Imatinib effectively controls tumor growth by inhibiting the c-KIT and PDGFR signaling pathways. For patients with unresectable or metastatic GIST, imatinib, as a first-line targeted therapy, can significantly extend the median progression-free survival and overall survival. In addition, adjuvant treatment with imatinib for patients with high-risk postoperative GIST can also significantly reduce the risk of tumor recurrence and improve long-term survival rates.

In addition to CML and GIST, imatinib has also shown efficacy in certain other rare diseases. For example, in some chronic eosinophilic leukemia, systemic eosinophilia, and platelet-derived growth factor-related myeloproliferative diseases, imatinib can improve patient symptoms and hematological indicators by inhibiting the PDGFR signaling pathway. Clinical practice shows that although the patient groups for these indications are small, imatinib can also exert a stable targeted therapeutic effect and significantly improve the quality of life of patients.

In general, imatinib is a multi-target tyrosine kinase inhibitor, mainly suitable for BCR-ABL positive chronic myelogenous leukemia, c-KIT or PDGFRα mutated gastrointestinal stromal tumors, and some rare myeloproliferative diseases related to platelet-derived growth factor. It specifically inhibits abnormal tyrosine kinase activity and blocks pathogenic signaling pathways, thereby controlling disease progression and prolonging patient survival. With the continuous deepening of clinical research and practice, the role of imatinib in the field of precision treatment has become increasingly clear, providing a safe and effective long-term treatment option for patients with many types of malignant tumors and hematological diseases.

Reference materials:https://www.drugs.com/